Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status

1 Department of Translational Biomedicine, Heriot Watt University, Edinburgh; 2 Division of Molecular Physiology, College of Life Sciences; 3 Department of Pharmacology and Neurosciences, University of Dundee; 4 Medical Research Council Protein Phosphorylation Unit, College of Life Sciences, Univers...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology: endocrinology and metabolism Vol. 296; no. 5; pp. E1042 - E1048
Main Authors Babraj, John Andree, Mustard, Kristy, Sutherland, Calum, Towler, Mhari C, Chen, Shaui, Smith, Kenneth, Green, Kevin, Leese, Graham, Hardie, David Grahame, Rennie, Michael J, Cuthbertson, Daniel James
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.05.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:1 Department of Translational Biomedicine, Heriot Watt University, Edinburgh; 2 Division of Molecular Physiology, College of Life Sciences; 3 Department of Pharmacology and Neurosciences, University of Dundee; 4 Medical Research Council Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dundee; 5 School of Biomedical Sciences, Graduate Entry Medical School, University of Nottingham, Derby City Hospital, Derby; 6 Department of Diabetes, Ninewells Hospital and Medical School, Dundee; and 7 Department of Diabetes, Clinical Sciences Centre, University Hospital Aintree, Liverpool Submitted 1 October 2008 ; accepted in final form 22 January 2009 We demonstrated previously that, in healthy young men, 5-aminoimidazole-4-carboxamide 1-β- D -ribofuranoside (AICAR) stimulates human muscle 2-deoxyglucose (2DG) uptake without detectable activation of muscle AMP-activated protein kinase (AMPK) but with extracellular-regulated kinase 1/2 (ERK1/2) activation. We tested whether AICAR stimulates muscle 2DG uptake in healthy older patients with or without type 2 diabetes (T2D). Six healthy young subjects (23 ± 3 yr, BMI 25 ± 2 kg/m –2 ; means ± SE), eight older subjects (59 ± 4 yr, BMI 28 ± 2 kg/m –2 ), and eight subjects with T2D (62 ± 4 yr, BMI 27 ± 2 kg/m –2 ) received a 6-h 2DG infusion (prime 10 mg/kg, 6 mg·kg –1 ·h –1 ) and AICAR (10 or 20 mg·kg –1 ·h –1 ) from 3 to 6 h. Quadriceps biopsies were taken at 0, 3, and 6 h. We determined 1 ) 2DG uptake, 2 ) total AMPK activity, AMPK, acetyl-CoA carboxylase (ACC), and AS160 phosphorylation, and 3 ) ERK1/2 phosphorylation. Ten milligrams per kilogram per hour AICAR increased 2DG uptake by 2.9 ± 0.7-fold in young men ( P < 0.001), 1.8 ± 0.2-fold in older men ( P < 0.01), and 1.6 ± 0.1-fold in men with T2D; 20 mg·kg –1 ·h –1 AICAR increases were 2.5 ± 0.1-fold (older men, P < 0.001) and 2.2 ± 0.2-fold (men with T2D, P < 0.001). At 3-h AMPK activity and AMPK, ACC and AS160 phosphorylation were unchanged, but ERK1/2 phosphorylation increased at both AICAR doses. The fold changes of ERK1/2 phosphorylation and 2DG uptake closely correlated ( R 2 = 0.55, P = 0.003). AICAR stimulates muscle 2DG uptake in T2D to the same extent as in healthy age-matched controls, but there is an age-related reduction. 5-aminoimidazole-4-carboxamide-1-β- D -ribofuranoside; adenosine 5'-monophosphate-activated protein kinase; extracellular-signal-regulated kinase 1/2 Address for reprint requests and other correspondence: D. Cuthbertson, Dept. of Diabetes, Clinical Sciences Centre, Univ. Hospital Aintree, Liverpool, L9 7AL, UK (e-mail: daniel.cuthbertson{at}liverpool.ac.uk )
Bibliography:Address for reprint requests and other correspondence: D. Cuthbertson, Dept. of Diabetes, Clinical Sciences Centre, Univ. Hospital Aintree, Liverpool, L9 7AL, UK (e-mail: daniel.cuthbertson@liverpool.ac.uk)
ISSN:0193-1849
1522-1555
DOI:10.1152/ajpendo.90811.2008